Limosilactobacillus reuteri 3613-1

Supports Vaginal and Urinary Tract Health

Urogenital tract infections, including acute or chronic urinary tract infections (UTIs) and genital tract infections, are common and often recurring health issues in women of reproductive age. Limosilactobacillus reuteri strain 3613-1 was identified from a library of over 6,000 lactic acid bacteria in the Arm & Hammer Research library as a unique strain due to its ability to produce antimicrobial metabolites.

The bacteriocin supernatant from L. reuteri 3613-1 demonstrated significant growth inhibition activity, against four tested Escherichia coli strains (3 human vaginal isolates and one human stool isolate) by more than 97%. Additionally, further studies found that L. reuteri 3613-1 inhibited the growth of Gardnerella vaginalis by over 90% and Candida albicans by more than 98%, outperforming a competitor L. reuteri strain.

A proof-of-principle trial was conducted in human participants to demonstrate the ability of this probiotic strain to reach the site of infection during UTIs when taken orally. Four college-aged females with recurring urinary tract infections took L. reuteri 3613-1 orally once daily for 60 days. Analysis of vaginal swabs confirmed that oral administration of L. reuteri 3613-1 survives passage through the gastrointestinal tract and can access and potentially colonize the vagina. None of the participants experienced UTIs during the 60-day treatment period, and the probiotic was well-tolerated with no adverse effects reported.

A randomized, double-blind, placebo-controlled study to assess the effects of Limosilactobacillus reuteri 3613-1 supplementation on the recurrence of urinary tract infections in healthy women over a six-month period has been completed. We invite you to review the results in the draft report available in the menu to the rightbelow.